Pharmaceutical Companies

Biogen Clinical Research Moderna REGENXBIO Bavarian Nordic Vaccine Development Market Performance Sinovant Sciences Drug Development Drug Testing Metabolic Health Sarepta Therapeutics Executive Leadership Capricor Therapeutics Clinical Research Organizations Clinical Development Market Analysis Roivant Sciences Public Offerings BBOT Covid-19 Vaccine Market Ocugen, Inc. UniQure Priovant Therapeutics Market Development Regulatory Affairs Regenxbio Transgene Amgen Psychedelic Drug Companies Moderna y Merck

3 ARTICLES

last mo.

Amgen’s Dazodalibep Meets Primary Goal in Phase 3 Sjögren’s Trial

The topline result raises the prospect of the first FDA‑approved therapy for Sjögren’s disease, with full data and a second Phase 3 readout determining approval chances.

7 ARTICLES

2mo ago

FDA Places Clinical Hold on REGENXBIO's RGX‑121 After Spine MRI Findings

3 ARTICLES

6mo ago

Avalo Therapeutics Reports Positive Phase 2 HS Results, Prices $375 Million Offering

3 ARTICLES

7mo ago

FDA Approves Higher‑Dose Spinraza Regimen for Spinal Muscular Atrophy

8 ARTICLES

8mo ago

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

6 ARTICLES

8mo ago

FDA Demands Placebo-Controlled Trial for UniQure’s Huntington’s Gene Therapy

3 ARTICLES

8mo ago

Ocugen Completes Phase III Enrollment for OCU400 and Targets Q3 2026 Rolling BLA

7 ARTICLES

9mo ago

FDA Rejects Filing of Moderna’s mRNA Flu Vaccine Over Comparator Dispute

4 ARTICLES

9mo ago

FDA Rejects Regenxbio’s Hunter Syndrome Gene Therapy Application

6 ARTICLES

last yr.

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

6 ARTICLES

last yr.

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research

8 ARTICLES

last yr.

Sarepta Halts Elevidys Shipments for Non-Ambulatory Patients After Second Fatal Liver Failure